Streetbeat News

Regulatory

AMD

ASML

INTC

NVDA

TSM

China has announced a $47.5 billion public fund to boost its self-reliance in manufacturing advanced chips, countering U.S. efforts to restrict its access to key technologies. The U.S. has also invested heavily in its semiconductor industry through the CHIPS Act, aiming to reduce reliance on Asian production and strengthen its geopolitical standing. Companies like NVIDIA, AMD, Intel, and Taiwan Semiconductor are mentioned as key players in the global semiconductor landscape.

Portfolio Pulse from Natan Ponieman

May 31, 2024 | 12:44 pm

RGF

The Real Good Food Company, Inc. (NASDAQ:RGF) has received a notice of non-compliance from Nasdaq due to its failure to timely file its Quarterly Report for the quarter ended March 31, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:41 pm

INBX

Trading for INBX was halted and then resumed at 8:40:00 AM ET. The halt was due to pending news, and trading has now resumed.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:40 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for its drug LIVMARLI for the treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) in patients three months and older. The decision is based on a Phase 3 study showing significant reduction in pruritus severity. A decision by the European Commission is expected in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:39 pm

OCGN

Ocugen announced that the Data and Safety Monitoring Board has recommended proceeding with dosing subsequent GA subjects with a low dose of OCU410 in the dose-expansion phase and concurrently initiating Phase 2 dosing.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:39 pm

SPY

The USA PCE price index for April came in at 0.3%, matching both the estimate and the prior month's figure.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:30 pm

NVS

Novartis' Scemblix (asciminib) has shown superior efficacy and a favorable safety profile compared to standard-of-care TKIs in a Phase III trial for newly diagnosed CML patients. The trial met both primary endpoints, demonstrating higher MMR rates and fewer adverse events. Scemblix has been granted US FDA Breakthrough Therapy Designation and is under review.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:20 pm

ITRM

Iterum Therapeutics shares are trading higher after the FDA acknowledged receipt of the company's resubmission of its New Drug Application for oral sulopenem.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:16 pm

MAXN

Maxeon Solar Technologies has regained compliance with Nasdaq Listing Rule 5250(c)(1) after filing its 2023 Annual Report. The company had previously received a notice of non-compliance due to a delayed filing.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:10 pm

LIPO

Lipella Pharmaceuticals has completed the site initiation visit for its Phase 2a trial of LP-310, a treatment for Oral Lichen Planus. Clinical testing is expected to begin in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 12:04 pm